

# Kent Academic Repository

## Full text document (pdf)

### Citation for published version

Raasakka, Arne and Ruskamo, Salla and Barker, Robert and Krokengen, Oda C. and Vatne, Guro H. and Kristiansen, Cecilie K. and Hallin, Erik I. and Skoda, M.W.A. and Bergmann, Ulrich and Wacklin-Knecht, Hanna and Jones, Nykola C and Hoffmann, Søren Vrønning and Kursula, Petri (2019) Neuropathy-Related Mutations Alter the Membrane Binding Properties of the human

### DOI

### Link to record in KAR

<https://kar.kent.ac.uk/73803/>

### Document Version

Author's Accepted Manuscript

#### Copyright & reuse

Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions for further reuse of content should be sought from the publisher, author or other copyright holder.

#### Versions of research

The version in the Kent Academic Repository may differ from the final published version.

Users are advised to check <http://kar.kent.ac.uk> for the status of the paper. **Users should always cite the published version of record.**

#### Enquiries

For any further enquiries regarding the licence status of this document, please contact:

[researchsupport@kent.ac.uk](mailto:researchsupport@kent.ac.uk)

If you believe this document infringes copyright then please contact the KAR admin team with the take-down information provided at <http://kar.kent.ac.uk/contact.html>

1 **Neuropathy-related mutations alter the membrane binding properties of the human**  
2 **myelin protein P0 cytoplasmic tail**

3

4 Arne Raasakka<sup>1</sup>, Salla Ruskamo<sup>2,3</sup>, Robert Barker<sup>4</sup>, Oda C. Krokengen<sup>1</sup>, Guro H. Vatne<sup>1</sup>, Cecilie K.  
5 Kristiansen<sup>1</sup>, Erik I. Hallin<sup>1</sup>, Maximilian W.A. Skoda<sup>5</sup>, Ulrich Bergmann<sup>2,3</sup>, Hanna Wacklin-  
6 Knecht<sup>6</sup>, Nykola C. Jones<sup>7</sup>, Søren Vrønning Hoffmann<sup>7</sup> & Petri Kursula<sup>1,2,\*</sup>

7

8 <sup>1</sup>Department of Biomedicine, University of Bergen, Bergen, Norway

9 <sup>2</sup>Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland

10 <sup>3</sup>Biocenter Oulu, University of Oulu, Oulu, Finland

11 <sup>4</sup>School of Physical Sciences, University of Kent, Kent, United Kingdom

12 <sup>5</sup>ISIS Neutron and Muon Source, Science & Technology Facilities Council, Rutherford Appleton Laboratory, OX11  
13 OQX Didcot, United Kingdom

14 <sup>6</sup>Division of Physical Chemistry, Department of Chemistry, Lund University & European Spallation Source ERIC,  
15 Lund, Sweden

16 <sup>7</sup>ISA, Department of Physics and Astronomy, Aarhus University, Ny Munkegade 120, 8000 Aarhus C, Denmark

17

18

19

20 \*Corresponding author. E-mail: petri.kursula@uib.no

21

22

1 **Abstract**

2 Schwann cells myelinate selected axons in the peripheral nervous system (PNS) and contribute to fast  
3 saltatory conduction via the formation of compact myelin, in which water is excluded from between tightly  
4 adhered lipid bilayers. Peripheral neuropathies, such as Charcot-Marie-Tooth disease (CMT) and Dejerine-  
5 Sottas syndrome (DSS), are incurable demyelinating conditions that result in pain, decrease in muscle mass,  
6 and functional impairment. Many Schwann cell proteins, which are directly involved in the stability of  
7 compact myelin or its development, are subject to mutations linked to these neuropathies. The most abundant  
8 PNS myelin protein is protein zero (P0); point mutations in this transmembrane protein cause CMT subtype  
9 1B and DSS. P0 tethers apposing lipid bilayers together through its extracellular immunoglobulin-like  
10 domain. Additionally, P0 contains a cytoplasmic tail (P0ct), which is membrane-associated and contributes  
11 to the physical properties of the lipid membrane. Six CMT- and DSS-associated missense mutations have  
12 been reported in P0ct. We generated recombinant disease mutant variants of P0ct and characterized them  
13 using biophysical methods. Compared to wild-type P0ct, some mutants have negligible differences in  
14 function and folding, while others highlight functionally important amino acids within P0ct. For example, the  
15 D224Y variant of P0ct induced tight membrane multilayer stacking. Our results show a putative molecular  
16 basis for the hypermyelinating phenotype observed in patients with this particular mutation and provide  
17 overall information on the effects of disease-linked mutations in a flexible, membrane-binding protein  
18 segment. Using neutron reflectometry, we additionally show that P0ct embeds deep into a lipid bilayer,  
19 explaining the observed effects of P0ct on the physical properties of the membrane.

20

21 **Keywords**

22 Myelin protein zero; membrane binding; peripheral neuropathy; CMT; DSS; disease mutation; gain of  
23 function

24

25

## 1 **Introduction**

2 Fast saltatory nerve impulse conduction requires myelin, a structure composed of tightly stacked lipid  
3 bilayers that wrap around selected axonal segments in the central and peripheral nervous systems (CNS and  
4 PNS, respectively). The insulative nature of myelin enables efficient nerve impulse propagation, and the  
5 destruction of myelin, demyelination, underlies a range of chronic diseases. In the PNS, peripheral  
6 neuropathies affect Schwann cell compact myelin. These include Charcot-Marie-Tooth disease (CMT) and  
7 its more severe, rapidly progressive form known as Dejerine-Sottas syndrome (DSS), which cause incurable  
8 chronic disability [1,2]. CMT and DSS manifest through both dominant and recessive inheritance, and they  
9 harbour a strong genetic component, typically caused by mutations in proteins relevant for the formation and  
10 stability of PNS myelin, while axonal forms also exist.

11 Myelin protein zero (P0) is a type I transmembrane protein consisting of an extracellular immunoglobulin  
12 (Ig)-like domain [3], a single transmembrane helix, and a 69-residue C-terminal cytoplasmic tail (P0ct). P0ct  
13 is likely to be involved in the regulation of myelin membrane behaviour, supporting the arrangement of the  
14 P0 Ig-like domains in the extracellular space upon the formation of the myelin intraperiod line [4–6]. P0ct  
15 contains a neuritogenic segment, which can be used to induce experimental autoimmune neuritis (EAN) in  
16 animal models [7]. In vitro, P0ct is disordered in aqueous solution, gaining secondary structure upon binding  
17 to negatively charged phospholipids [4,5]. In its lipid-bound state, P0ct affects the phase behaviour of lipids  
18 and promotes the fusion of lipid vesicles. High-degree molecular order, most likely from stacked lipid  
19 bilayers, can be detected via X-ray diffraction of P0ct-bound membranes [5]. This suggests that P0ct  
20 harbours a structural role in mature myelin.

21 Dozens of mutations have been identified in P0, most of which affect the Ig-like domain. These mutations  
22 affect myelin morphology and integrity, leading to the development of peripheral neuropathies [8,9]. Six  
23 known missense mutations are located within P0ct, of which four cause dominant demyelinating CMT type  
24 1B (CMT1B). These include T216ER [10], D224Y (also referred to as D195Y and D234Y) [11–13], R227S  
25 [9], and the deletion of Lys236 (K236del) [14]. In addition, K236E has been linked to dominant axonal CMT  
26 type 2I (CMT2I) [15], and A221T, which was discovered as a co-mutation together with the deletion of  
27 Val42 in the Ig-like domain, was identified in a patient with DSS [16]. How these mutations relate to  
28 CMT/DSS etiology is not known, although P0 mutations have been linked to the unfolded protein response  
29 (UPR) [17–19], indicating issues in either translation or folding that induce stress within the endoplasmic  
30 reticulum (ER).

31 Considering the small size of P0ct and the nature of the disease mutations in it, many of which change its  
32 electrostatic charge, impairment in the function of P0ct as a membrane binding/stabilizing segment is a  
33 possible functional mechanism. We used methodologies established earlier for myelin basic protein (MBP)  
34 [20] and wild-type P0ct (wt-P0ct) [5,21] to characterize structure-function relationships of the CMT- and

1 DSS-related P0ct variants. Our results suggest that D224Y is a hypermyelinating gain-of-function mutation,  
2 which is in line with the clinically relevant phenotype of abnormally thick myelin sheaths [11].

3

4

## 1 **Results**

2 We earlier studied the binding of MBP and P0ct to model lipid membranes [5,20,21], using a biophysical  
3 workflow that allows the determination of binding affinity, level of folding, alteration of lipid phase  
4 behaviour, quantification and visualization of vesicle aggregation and fusion, and supported lipid bilayer  
5 (SLB) stacking. In the current study, we examined whether and how CMT and DSS mutations within P0ct  
6 influence its structure and function. For this purpose, we expressed and purified the wild-type protein and six  
7 mutant variants, each harbouring one of the following amino acid changes: T216ER, A221T, D224Y,  
8 R227S, K236E, and K236del.

9

### 10 **Characterization of P0ct CMT mutants**

11 wt-P0ct and the six CMT variants were purified to homogeneity. Most mutants were straightforward to  
12 purify, showing identical behaviour to wt-P0ct in size-exclusion chromatography (SEC) (Fig. 1b). D224Y,  
13 on the other hand, had to be gel filtered at a higher pH and salt concentration than the others, and while  
14 yields were generally lower, minor amounts of degradation were present and the migration in SEC was  
15 altered, albeit not in denaturing gel electrophoresis (SDS-PAGE) (Fig. 1b. Supplementary Fig. S1). In  
16 dynamic light scattering (DLS), all variants displayed a similar hydrodynamic radius ( $R_h$ ) and an absence of  
17 aggregation (Fig. 1c, Supplementary Table S1). All of the variants showed high apparent molecular weight  
18 in SDS-PAGE, which reflects the intrinsically disordered nature of P0ct [5]. The molecular weight and the  
19 presence of the mutations were confirmed using mass spectrometry (Table 1). The total yields of the purified  
20 mutant proteins were different from wt-P0ct (Supplementary Fig. S1, Table 1), most mutants giving larger  
21 yields, with the exception of D224Y. It should be noted that all mutants were expressed as maltose-binding  
22 protein fusions. Thus, mutations, which represent small changes in the overall sequence and size of the  
23 fusion protein, can affect the expression and purification behaviour.

24

25 **Fig. 1. Overview of P0ct mutations.** (a) The sequence of the wt-P0ct construct, corresponding to amino  
26 acids 180 – 248 of the human P0 precursor, with an extra N-terminal Gly residue (gray) left behind from  
27 affinity tag cleavage. The Cys182 palmitoylation site was mutated into a Leu (green) in all constructs.  
28 Putative serine phosphorylation sites are indicated with asterisks. Residues affected by disease mutations are  
29 in bold. CMT1B, CMT2I, and DSS point mutations are shown in blue, red, and orange, respectively. The  
30 sequence highlighted in yellow corresponds to the neuritogenic segment used in EAN models [7]. Secondary  
31 structure prediction is shown below. (b) SEC traces of wt-P0ct and mutants as determined using a Superdex  
32 75 10/300GL column. Note the slightly lower retention volume of D224Y, for which the chromatography  
33 had to be performed with a different running buffer than for the other variants. The degradation products (red  
34 asterisk) present with D224Y could be completely removed using SEC. The final purity of each P0ct variant

1 (4  $\mu\text{g}$  per lane) as determined using SDS-PAGE is shown as inset. (c) DLS data of P0ct variants display good  
 2 monodispersity with minimal variation in  $R_h$ .

3

4 **Table 1. Recombinant protein characterization.**

Variant*	Condition	pI**	Purification		Molecular weight determination			Peptide fingerprinting
			Yield***	Solubility	Measured	Theoretical**	Difference	Mutation confirmed
wt-P0ct	-	11.11	2.1 $\pm$ 0.4	++	7989.0	7990.35	-1.35	-
T216ER	CMT1	11.08	4.2 $\pm$ 0.4	+++	8173.0	8174.54	-1.54	yes
A221T	DSS	11.11	5.0 $\pm$ 0.7	+++	8018.0	8020.37	-2.37	yes
D224Y	CMT1	11.12	0.8 $\pm$ 0.3	+	8037.0	8038.43	-1.43	yes
R227S	CMT1	10.89	6.1 $\pm$ 2.0	+++	7919.0	7921.24	-2.24	yes
K236E	CMT2	10.85	5.1 $\pm$ 1.8	+++	7989.0	7991.29	-2.29	yes
K236del	CMT1	11.09	5.2 $\pm$ 1.0	+++	7860.0	7862.17	-2.17	yes

5 \*All proteins, including wt-P0ct, contain the C182L mutation.

6 \*\*Values determined from protein sequences using ProtParam

7 \*\*\*Expressed as mg protein obtained on average per liter culture. See Supplementary Fig. 1 for graphical  
 8 representation.

9

10 Small-angle X-ray scattering (SAXS) verified that for most variants, both the size and behaviour in solution  
 11 were nearly identical, with radius of gyration ( $R_g$ ) and maximum dimension ( $D_{\text{max}}$ ) at 2.4 - 2.7 nm and 9.0 –  
 12 10.7 nm, respectively, and molecular masses matching monomeric protein based on  $I_0$  values (Fig. 2,  
 13 Supplementary Table S2). D224Y presented a marginally larger  $D_{\text{max}}$  (11.6 nm) compared to the other  
 14 variants, but all variants were flexible and extended in solution, as evident from the Kratky plot (Fig. 2d).

15

16 **Fig. 2. SAXS analysis of P0ct in solution.** (a) SAXS data for P0ct variants. The scattering curves have been  
 17 offset for clarity. (b) Guinier fits based on SAXS data. Data range is shown within each graph. (c) Distance  
 18 distributions. (d) Kratky plots. P0ct variant data point coloring is consistent throughout the figure. GNOM  
 19 fits to the data are shown as black lines in panels (a) and (c).

20

## 21 **The folding and lipid binding properties of P0ct CMT mutants**

22 To compare the conformation of the P0ct variants, we carried out a series of synchrotron radiation circular  
 23 dichroism (SRCD) spectroscopic experiments in the absence and presence of different lipid compositions,  
 24 detergents, and 2,2,2-trifluoroethanol (TFE), as previously described for wt-P0ct [5]. P0ct is disordered in  
 25 solution and gains a significant amount of secondary structure upon binding to small unilamellar vesicles  
 26 (SUV) with a net negative surface charge [4,5]. In water, all mutants were disordered as expected, with

1 D224Y having less secondary structure than the others (Fig. 3). This is in agreement with the longer  $D_{\max}$   
2 determined using SAXS. All mutants closely resembled wt-P0ct in TFE and the detergents sodium dodecyl  
3 sulphate (SDS), n-dodecylphosphocholine (DPC), lauryldimethylamine N-oxide (LDAO), and n-octyl  
4 glucoside (OG) (Fig. 3, Supplementary Fig. S2). K236del was more  $\alpha$ -helical than the other variants in the  
5 presence of SDS (Fig. 3c), as evidenced by both the larger spectral amplitude and the slight change in peak  
6 position towards a higher wavelength.

7

8 **Fig. 3. Folding and lipid binding analysis of P0ct variants.** The folding of wt-P0ct and mutants was  
9 studied using SRCD spectropolarimetry in (a) water, (b) 30% TFE, (c) 0.5% SDS, (d) DMPC:DMPG (1:1),  
10 and (e) DMPC:DMPG (4:1) at 1:200 P/L ratio in each lipid condition. Additional spectra are presented in  
11 Supplementary Fig. S2. (f) SPR measurements were used to determine the affinity of each P0ct variant to  
12 immobilized DMPC:DMPG (1:1) vesicles. The colour coding legend in panel (a) for each mutant trace also  
13 corresponds to all other traces in subsequent panels.

14

15 Addition of DMPC retained the proteins in a disordered state, with D224Y deviating slightly (Supplementary  
16 Fig. S2). In the presence of net negatively charged SUVs composed of DMPC:DMPG ratios of 1:1, 4:1, and  
17 9:1, the variants presented some folding differences (Fig. 3, Supplementary Fig. S2). Overall, most folding  
18 was observed in 1:1 DMPC:DMPG, and the degree of folding decreased with decreasing fraction of DMPG,  
19 i.e. negative charge. In DMPC:DMPG (1:1), a small shift to the right of the maximum at 188 nm was evident  
20 for D224Y and K236del, indicating slightly increased folding, although the two minima at 208 and 222 nm,  
21 typical for helical content, remained the same for all variants (Fig. 3d). In DMPC:DMPG (4:1), this effect  
22 was only observed for D224Y (Fig. 3e). In DMPC:DMPG (9:1), the differences in signal magnitude were  
23 large, reflecting different levels of turbidity (Supplementary Fig. S2). It can be assumed that the variants  
24 showing high turbidity under this condition are membrane-bound, while the ones giving strong CD signal of  
25 an unfolded protein do not bind to 9:1 DMPC:DMPG.

26 The affinity of P0ct variants towards immobilized DMPC:DMPG (1:1) SUVs was investigated using surface  
27 plasmon resonance (SPR). All variants bound to lipids with similar kinetic parameters (Fig. 3f, Table 2),  
28 including the  $A_1$  value, which corresponds to the apparent  $K_d$ , of 0.35-0.4  $\mu\text{M}$ . This value is in the same range  
29 with those obtained earlier for wt-P0ct, MBP, and P2 [5,20,22,23]. While the differences in  $K_d$  were minor,  
30 the behaviour of D224Y was unique: the observed maximal response level was higher compared to the other  
31 variants. This suggests that the D224Y variant can either accumulate onto immobilized vesicles in higher  
32 amounts, or it induces a change on the surface that affects the measurement, such as the fusion, swelling, or  
33 aggregation of lipid vesicles.

34



1 **Table 2. SPR fitting parameters.**

Variant	R <sub>hi</sub>	R <sub>lo</sub>	A <sub>1</sub>	A <sub>2</sub>	R <sup>2</sup>
wt-P0ct	2975 ± 79	-69.1 ± 61.5	363.2 ± 15.1	3.24 ± 0.41	0.986
T216ER	3123 ± 86	-44.6 ± 64.2	375.1 ± 15.6	3.17 ± 0.41	0.985
A221T	3061 ± 82	-44.8 ± 62.3	357.0 ± 15.5	2.97 ± 0.36	0.986
D224Y	3811 ± 81	11.3 ± 66.3	385.2 ± 11.3	4.42 ± 0.54	0.989
R227S	2798 ± 78	-39.5 ± 55.2	384.9 ± 16.0	2.94 ± 0.36	0.986
K236E	2671 ± 92	-49.5 ± 60.0	380.8 ± 20.0	2.53 ± 0.34	0.983
K236del	2880 ± 79	-33.9 ± 58.9	356.1 ± 16.0	2.85 ± 0.35	0.986

2

3

4 **Effect of CMT mutations on lipid membrane properties**

5 To determine the effect of the mutations on lipid structure, experiments probing changes in the  
6 thermodynamic and structural properties of lipid membranes were carried out. As shown before [5], the  
7 presence of P0ct changes the melting behaviour of dimyristoyl lipid tails, inducing a population that melts  
8 0.9 °C below the major phase transition temperature of 23.8 °C. The presence of the mutations altered this  
9 effect mildly (Fig. 4a), with T216ER and R227S behaving similarly to wt-P0ct. The Lys236 mutations  
10 deviated from wt-P0ct, with a decreased temperature for the emerged population; K236E and K236del  
11 showed lipid phase transition temperatures of ~22.8 °C. A221T presented a slightly higher temperature for  
12 phase transition compared to wt-P0ct, with the major peak at 23.1 °C. Based on the shape of the calorimetric  
13 landscape, D224Y was clearly different from the rest, as the new population did not appear as a single, sharp,  
14 symmetric peak, but was rather formed of several overlapping peaks. The fitted phase transition temperatures  
15 and associated errors are given in Supplementary Table S3.

16

17 **Fig. 4. Analysis of protein-induced lipid structure behaviour.** (a) DSC analysis of lipid phase transition.  
18 The experiments were carried out at 350 µM DMPC:DMPG (1:1) and a 1:100 P/L ratio. (b) Turbidimetric  
19 analysis of 0.5 mM DMPC:DMPG (1:1) at 5 µM (gray) and 10 µM protein concentration (dark red). These  
20 proteins concentrations translate to 1:100 and 1:50 P/L ratios, respectively. Error bars represent standard  
21 deviation. Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by  
22 Dunnett's multiple comparisons test to wt-P0ct turbidity within the same protein concentration series (\* : P <  
23 0.05; \*\*\* : P < 0.001). (c) SAXD analysis reveals that D224Y displays a significantly tighter mean repeat  
24 distance compared to wt-P0ct, whereas K236E is most loose. The traces have identical colouring to (a).

25

26 Similarly to MBP and P2 [20,22], P0ct is capable of inducing concentration-dependent solution  
27 turbidification, when mixed with lipid vesicles of net negative charge [5]. The turbidity can arise from  
28 vesicle fusion and/or aggregation, and different processes may be dominant in different samples with respect

1 to the measured signal. To determine the effect of P0ct CMT mutations on this function, turbidity  
2 experiments were carried out with the different variants. T216ER and A221T produced turbidity levels  
3 similar to wt-P0ct (Fig. 4b, Supplementary Fig. S3a). At 1:100 P/L ratio, D224Y, R227S, K236E, and  
4 K236del all had decreased turbidity. At a P/L ratio of 1:50, however, only D224Y had a significant  
5 inhibitory effect on turbidity. This result highlights that the D224Y mutant protein may function differently  
6 from the other variants, when it binds to and aggregates vesicles.

7 To shed further light on the protein-induced changes in membrane structure, small-angle X-ray diffraction  
8 (SAXD) experiments were performed on P0ct-membrane mixtures. In our earlier study, wt-P0ct mixed with  
9 lipids produced two strong Bragg peaks, and the corresponding repeat distance evolved as a function of the  
10 P/L ratio [5]. Here, we observed that in all cases, the repeat distance increased when protein concentration in  
11 the sample decreased (Fig. 4c, Supplementary Fig. S3b). Each variant presented a minimum repeat distance,  
12 which was reached at and above a P/L ratio of 1:100. The repeat distance for wt-P0ct was ~7.5 nm, while  
13 D224Y produced a spacing of <7.0 nm. R224S, K236E, and K236del had looser packing than wt-P0ct.  
14 K236E had a minimum repeat distance of ~8.0 nm at the highest protein concentration.

15 To understand the effect of the mutations on the function of P0ct, and the origin of the high molecular order  
16 reflected by X-ray diffraction, electron microscopy imaging was performed. Most mutants functioned in a  
17 manner similar to wt-P0ct, producing large vesicular structures with a spread-out morphology (Fig. 5), with  
18 occasional regions indicative of bilayer stacking. D224Y showed a clear difference to wt-P0ct, producing  
19 strongly stacked myelin-like membranes in a manner resembling MBP [20]. This gain of function was  
20 reproducible over a wide range of P/L ratios (Supplementary Fig. S4) and a unique feature among the six  
21 mutant P0ct variants. The results confirm that the Bragg peaks seen in SAXD, indeed, originate from repeat  
22 distances in membrane multilayers, identically to two other PNS myelin peripheral membrane proteins, MBP  
23 and P2 [20,22,24]. The observed bilayer spacing for the D224Y mutant in EM was narrow and in general  
24 better defined than seen for MBP [20], suggesting that P0ct forms a tight structure within and/or between the  
25 membranes. Based on SAXD, the intermembrane spacing is ~3 nm, a value in close relation to the  
26 dimensions of the major dense line (MDL) in myelin *in vivo*.

27

28 **Fig. 5. EM analysis of P0ct mutants.** Negatively stained samples of DMPC:DMPG (1:1) vesicles were  
29 imaged (a) alone, and with (b) wt-P0ct, (c) T216ER, (d) A221T, (e) D224Y, (f) R227S, (g) K236E, and (h)  
30 K236del at a 1:200 P/L ratio. D224Y forms multilayered lipid structures that are absent for wt-P0ct.

31

32 To gain insight into the kinetic aspects of P0ct-induced lipid fusion/aggregation, stopped-flow kinetics  
33 experiments were performed using SRCF (Fig. 6, Table 3) [21]. All variants followed a similar kinetic  
34 pattern as wt-P0ct and could be best fitted to a two-phase exponential decay with two rate constants ( $k_1$ , fast

1 and  $k_2$ , slow). Rather minor differences were present:  $k_2$  values were very similar in all cases, and while  
 2 D224Y presented 10% higher  $k_1$  and  $k_1/k_2$  compared to wt-P0ct and most other variants, both K236E and  
 3 K236del displayed  $k_1$  and  $k_1/k_2$  20% lower than for wt-P0ct, indicating slower kinetics (Fig. 6b). While all  
 4 variants produced a similar end-level CD value around -100 mdeg at 195 nm wavelength, the starting level  
 5 for K236del was higher than for any other variant, and remained so until ~0.3 s, before settling on a level  
 6 similar to other variants. It is currently unclear whether this is due to an increased level of protein folding or  
 7 less scattered light from fused or aggregated vesicles.

8

9 **Fig. 6. SRCD stopped-flow kinetics of protein-induced initial lipid turbidification.** (a) The SRCD signal  
 10 at 195 nm was monitored using rapid kinetics for 5 s. wt-P0ct and mutants were mixed with DMPC:DMPG  
 11 (1:1) lipids at 1:200 P/L ratio in the presence of 150 mM NaF. Fits (dashed lines) are plotted over the  
 12 measurement points. Error bars represent standard deviation. See Table 4 for fitting results. (b) Graphical  
 13 comparison of the obtained  $k_1$  values.

14

15 **Table 3. Kinetic constants for protein-induced vesicle turbidity.** The kinetic constants were obtained by  
 16 fitting the data to a two-phase exponential decay function. All errors represent standard deviation.

17

Variant	$k_1$ ( $s^{-1}$ )	$k_2$ ( $s^{-1}$ )	$k_1/k_2$	$R^2$
wt-P0ct	$20.14 \pm 0.25$	$1.12 \pm 0.01$	$17.96 \pm 0.22$	0.993
T216ER	$19.54 \pm 0.28$	$1.18 \pm 0.02$	$16.63 \pm 0.25$	0.991
A221T	$19.15 \pm 0.21$	$1.14 \pm 0.01$	$16.76 \pm 0.20$	0.994
D224Y	$22.11 \pm 0.28$	$1.19 \pm 0.02$	$18.53 \pm 0.25$	0.992
R227S	$19.35 \pm 0.27$	$1.08 \pm 0.02$	$17.95 \pm 0.26$	0.992
K236E	$14.98 \pm 0.12$	$1.02 \pm 0.01$	$14.64 \pm 0.13$	0.997
K236del	$14.25 \pm 0.12$	$1.05 \pm 0.01$	$13.54 \pm 0.13$	0.997

18

### 19 **The membrane insertion mode of P0ct**

20 To understand the membrane insertion of P0ct, how it compares to MBP [20], and how it might be related to  
 21 disease mutations, we performed neutron reflectometry (NR) experiments (Fig. 7, Table 4). The insertion of  
 22 P0ct to a DMPC:DMPG SLB was quite different to that of MBP. P0ct inserted completely into the  
 23 membrane, thickening it by 2 nm and increasing its roughness, most likely due to increased bilayer mobility,  
 24 as the hydration layer below the membrane became thicker (Fig. 7b,c). P0ct was present in the acyl tail  
 25 fraction of the membrane, as well as in the outer headgroup fraction. The data could not be fitted with only  
 26 these parameters, but a very rough, narrow layer of protein had to be considered on top of the membrane.  
 27 Unfortunately, the roughness and high solvation fraction of this layer did not allow for precise thickness  
 28 determination: the layer was modelled to be between 5 – 15 Å thick within the fit to the data. To investigate

1 the effect of the D224Y mutation on P0ct membrane association, NR data were collected for SLB-bound  
 2 D224Y, which appeared identical to wt-P0ct (Supplementary Fig. S5).

3

4 **Fig. 7. Neutron reflectometry.** (a) NR data for a supported DMPC:DMPG (1:1) bilayer before (open  
 5 markers) and after incubation with wt-P0ct (closed markers). The solvent contrasts used were 95% D<sub>2</sub>O  
 6 (red), Si-matched water (SMW, 38% D<sub>2</sub>O; green), and 100% H<sub>2</sub>O (blue). The error bars denote standard  
 7 deviation. Fits are shown as dashed and solid lines for the bilayer before and after addition of wt-P0ct,  
 8 respectively. (b) Scattering length density ( $\rho$ ) profiles obtained from the fitting. (c) Model for the P0ct-bound  
 9 membrane. The protein-free membrane is shown in light gray on the background.

10 **Table 4. NR fitting parameters.** The fits and obtained scattering length density profiles are shown in Fig. 7.

		<b>Bilayer alone</b>	<b>Bilayer with 0.5 <math>\mu</math>M wt-P0ct</b>
<b>Substrate</b>	Oxide thickness ( $\text{\AA}$ )	10.6	11
	Oxide solvation (%)	0	0
	Oxide roughness ( $\text{\AA}$ )	4	4
	Hydration layer between oxide and bilayer ( $\text{\AA}$ )	4.6	12
	Hydration layer roughness ( $\text{\AA}$ )	3	6
<b>Bilayer</b>	Bilayer area-per-molecule ( $\text{\AA}^2/\text{molecule}$ )	60	70
	Inner headgroups thickness ( $\text{\AA}$ )	8.3	8
	Inner headgroups roughness ( $\text{\AA}$ )	3.6	8.1
	Inner headgroups solvation (%)	35	45
	Acyl tails thickness ( $\text{\AA}$ )	28.8	32
	Acyl tails roughness ( $\text{\AA}$ )	3.8	13.3
	Acyl tails hydration (%)	0	17
	Outer headgroups thickness ( $\text{\AA}$ )	8.8	8
	Outer headgroups roughness ( $\text{\AA}$ )	4.9	9.5
	Outer headgroups solvation (%)	35	53.5
<b>wt-P0ct</b>	Protein in inner headgroups (%)	-	0
	Protein in acyl tails (%)	-	10
	Protein in outer headgroups (%)	-	20
	Protein layer thickness ( $\text{\AA}$ )	-	7
	Protein layer roughness ( $\text{\AA}$ )	-	15
	Protein layer solvation (%)	-	86

11

## 12 **Sequence analysis and modelling**

13 For a further insight into the molecular basis of the differences between P0ct variants, we carried out  
 14 computational analyses on P0ct sequence and folding. A sequence alignment of P0ct from different  
 15 vertebrate species (Fig. 8a) showed full conservation of certain segments of the sequence; specifically, all  
 16 mutated residues studied here with the exception of Thr216 are fully conserved across the species studied.

1 The region carrying the mutations, corresponding to the neuritogenic segment and predicted to fold into a  
2 membrane-binding helix, is strongly predicted to fold upon binding (Fig. 8b). Our earlier data showed that  
3 this peptide segment inserts into the membrane in a tilted helical conformation [5]. In the predicted  
4 membrane-embedded tilted helix, Asp224 and Arg227 are on the same face of the helix, next to Tyr220 (Fig.  
5 8c). In such a helix, Asp224 and Arg227 are likely to form a salt bridge, while the other end of the helix  
6 would be embedded in the membrane.

7

8 **Fig. 8. Sequence analysis of P0ct.** (a) Alignment of P0ct from selected vertebrates. The locations of the P0ct  
9 mutations are indicated with arrowheads. (b) ANCHOR2/IUPred2 analysis of P0ct highlights a region likely  
10 to fold upon ligand binding between residues 215-230. (c) Stereo view of a model of the predicted  
11 membrane-binding helical region. Hydrogen bonds are shown with thin blue lines.

12

13 The effects of the mutations D224Y and R227S can be partly rationalized based on this simple model (Fig.  
14 9a). D224Y would result in two Tyr residues next to each other facing the apposing membrane together with  
15 an Arg residue - this could change the membrane properties, such that stacking interactions are stronger and  
16 hypermyelination can occur. On the other hand, R227S will expose a free negative charge on Asp224, which  
17 should be repulsive towards an apposing negatively charged bilayer surface. When the region 216-229 is  
18 modelled as a helix and subjected to MD simulations in water, differences in folding propensity are observed  
19 with these mutations (Fig. 9b). While wild-type and R227S rapidly lose helical conformation, D224Y  
20 remains mainly helical throughout the 500-ns simulation, possibly indicating a more stable helix in the  
21 mutant protein. Whether this is the case for a membrane-embedded helix in P0ct, is currently unknown. A  
22 schematic model of P0ct on a membrane surface is shown in Fig. 9c.

23

24 **Fig. 9. Models for P0ct.** (a) Tentative models of the membrane-embedded P0ct helix with the two mutations  
25 having opposite effects on membrane stacking. The tilted orientation is estimated based on earlier oriented  
26 CD experiments on wt-P0ct [5]. (b) MD simulations starting from a helical structure in water. Blue,  $\alpha$  helix;  
27 orange, coil; green, turn; light blue,  $\beta$  strand; yellow,  $3_{10}$  helix. (c) A working model for the binding of P0ct  
28 to the membrane cytosolic surface, based on current knowledge and predictions. It is likely that the C-  
29 terminal region, including Lys236, is less tightly bound to the surface. Positions of the mutations studied in  
30 the current work are indicated with red arrows.

31

## 1 **Discussion**

2 The formation of compact myelin and the major dense line requires an interplay of myelin proteins, many of  
3 which have similar functional properties despite lack of sequence homology. Considering the MDL of PNS  
4 compact myelin, the major protein components according to current knowledge are MBP, P2, P0ct, and  
5 cytosolic loops of PMP-22. We characterized the potential functional anomalies of P0ct CMT mutants in  
6 membrane binding using earlier established biophysical strategies [5,20,21].

7 The six mutations reported in P0ct are clustered within or near the neuritogenic segment. Most of them  
8 reside in the vicinity of putatively phosphorylated Ser residues (Fig. 1a), which may be affected by P0ct  
9 mutations [10,25]. Many P0 mutations have been suggested to lead to UPR activation [17–19], indicating  
10 problems with translation rate, folding, and/or membrane insertion. Given the fact that P0ct is known to  
11 interact with lipid membrane surfaces [4,5,21], mutations within P0ct could also have direct effects on the  
12 formation of mature compact myelin at the molecular level.

### 13 **Mechanism of P0ct binding to membranes**

14 In order to fully understand the effects of P0ct mutations on its structure and function, detailed knowledge  
15 about P0ct binding to lipid membranes, and the effects thereof on multilayered membrane stacks, is required.  
16 NR allowed us to gain a picture of P0ct in a lipid bilayer. P0ct inserts deep into a membrane, with only a  
17 small fraction remaining solvent-exposed on the membrane surface. This is a clear difference to MBP, which  
18 forms a brush-like protein phase on top of the membrane surface, while being partially embedded into the  
19 bilayer [20]. After undergoing charge neutralization and folding, P0ct seems to collapse into a tight  
20 conformation and remain stable. The compact, deep conformation of P0ct suggests that instead of directly  
21 embedding into two bilayers, which is the working model for e.g. MBP-induced stacking [20,26], P0ct may  
22 change the surface properties of the membrane in a way that supports apposing bilayer surface adhesion. It  
23 could also regulate membrane curvature and the twining of lipid bilayers around the axon.

24 At the level of full-length P0, P0ct is a direct extension of the transmembrane segment, and hence, anchored  
25 permanently to a membrane surface at its beginning. Membrane stacking could, in theory, involve the  
26 insertion of P0ct across the MDL into an apposing membrane leaflet, which is only 3 nm away. Considering  
27 this scenario, it must be taken into account that P0 is basally expressed in Schwann cells even before  
28 myelination occurs [27]. Moreover, P0 is translated and inserted into the ER membrane and trafficked  
29 through the trans-Golgi network to the plasma membrane after the Ig-like domain has been post-  
30 translationally modified [28,29]. If P0ct were to enter an apposing membrane during the formation of  
31 compact myelin, it would have to remain in a disordered state until another membrane is present. On the  
32 other hand, if P0ct is embedded in the membrane after translation, it might afterwards be able to dissociate  
33 and enter the apposing leaflet within compact myelin. Considering the attractive phospholipid bilayer around  
34 the transmembrane helix, and the fact that P0ct binds negatively charged lipids essentially irreversibly in

1 vitro [5], both mechanisms described above are unlikely to exist. Thus, the role of P0ct in membrane  
2 adhesion is likely to be based on altered lipid membrane properties, as opposed to MBP and P2, which  
3 directly interact with two membrane surfaces. While P2 and MBP synergistically stack lipid bilayers in vitro  
4 [30], mice lacking both proteins formed apparently normal and functional myelin [31]. Hence, multiple  
5 factors must participate in the correct formation of compact myelin; these include both the lipid components  
6 of the myelin membrane, different myelin proteins, as well as signalling molecules and inorganic ions.  
7 Hence, further experiments in more complex sample environments are required to decipher the details of the  
8 molecular interplay between these factors in PNS myelin MDL formation.

### 9 **P0ct mutations and membrane interactions**

10 Compared to wt-P0ct, we observed only subtle differences for two mutants: T216ER and A221T. While  
11 T216ER behaved very similarly to wt-P0ct, its role in CMT etiology could be of another origin than related  
12 to protein-membrane binding. A221T, on the other hand, resides in the YAML-motif, which directs the  
13 trafficking of P0 [32] and might compromise the function of P0 even without inducing changes in membrane  
14 binding, especially when combined with a second mutation in the extracellular domain, such as the deletion  
15 of Val42 [16].

16 Functionally, the most interesting mutant studied here is D224Y, which has been described in at least 3  
17 studies [11–13]. Our results show it is a gain-of-function mutant, inducing ordered lipid bilayer stacks in  
18 vitro, which are more tightly packed than those formed by wt-P0ct or the other variants. Importantly, the  
19 affinity of the tightly packed membrane bilayers with the D224Y mutant towards each other is high enough  
20 to allow visualization of the ordered multilayers by EM, which was a striking difference to all other variants  
21 studied. The results correlate well the hypermyelinating disease phenotype [11]. Neutron reflectometry  
22 produced a nearly identical result for D224Y compared to wt-P0ct, which together with the SRCD  
23 experiments indicates that the conformation and level of insertion of wt-P0ct and D224Y are similar in the  
24 membrane. Small changes, not detectable by these methods, may however occur. The change of an acidic to  
25 an aromatic residue near the lipid bilayer surface could enable a specific interaction between surfaces that  
26 results in the observed gain of function. In this case, two vicinal aromatic residues on P0ct (Fig. 9a) might  
27 enhance membrane interactions, perhaps in a fashion similar to the tandem Phe motifs in MBP [33]. The fine  
28 molecular details of the effects causing tighter membrane stacking by the D224Y mutant protein, however,  
29 remain uncovered at the moment. There could exist differences in the orientation of the embedded helix in  
30 wt-P0ct and D224Y, for example. Both electrostatic forces, hydrophobic interactions, and aromatic stacking  
31 are likely involved in the altered proteolipid multilayer. Interactions of the protein with both of the apposing  
32 membranes could be affected by the mutation directly or indirectly, and these effects may be linked to the  
33 observed differences in the physicochemical behaviour of the lipid bilayer itself.

34 P0 is the most abundant protein in PNS myelin [34,35], contributing primarily to the formation of the  
35 intraperiod line [36], and molecular mechanisms of D224Y-induced tight stacking could be two-fold. Firstly,

1 with its short repeat distance – 1-2 nm smaller compared to MBP and P2 based on SAXD [5,22,24] – and  
2 active membrane binding, as evident from SPR, the mutant might cause size exclusion of P2 and other  
3 factors out of the cytoplasmic stack, leading to defective compact myelin maintenance. In PNS compact  
4 myelin, P2 is even more abundant in the cytoplasmic compartment than MBP, can form membrane stacks,  
5 and harbours a maintenance role in myelin homeostasis as a lipid carrier [22,31]. Secondly, the tendency of  
6 D224Y to form such ordered, tight systems might affect the Ig-like domains on the extracellular side. In the  
7 hypermyelinating phenotype of D224Y patients, membrane stacking seems condensed and regular, without  
8 abnormally loosened myelin [11]. SPR indicates that more D224Y can accumulate on membranes, and full-  
9 length P0 D224Y could accumulate and tighten up within the membrane, causing the intraperiod line to  
10 become more crowded and/or structured. The original discovery of the D224Y mutation [11] suggested that  
11 it has a gene dosage effect, since heterozygous carriers presented little to no symptoms. Hence, the presence  
12 of wild-type P0 can rescue the effects of the mutation. Correct gene dosage of P0 is important for normal  
13 myelination in animal models as well as CMT patients [11,37–41]. The molecular details of the involved  
14 mechanisms are currently lacking. Further studies on the D224Y mutation both in vitro, in silico, and in vivo  
15 will help in understanding molecular aspects of both normal and abnormal myelination.

16 Lys236 appears to be a functionally important amino acid in P0ct. In its membrane-bound state, P0ct is likely  
17 to have Lys236 close to the lipid headgroups (Fig. 9c), and altering the charge in this environment might  
18 influence folding and the global positioning of P0ct on the membrane. Indeed, a gradual effect in membrane  
19 packing was observed in SAXD; the repeat structure loosens, as residue 236 neutralizes (K236del) and turns  
20 to negative (K236E). Turbidimetry also indicated a clear effect of charge reversal at residue 236. The Lys236  
21 mutants folded to a similar degree as wt-P0ct, which suggests that the role of Lys236 is in membrane  
22 packing, rather than protein folding. This is supported by the slower kinetic parameters for Lys236 mutants  
23 in stopped-flow SRCD measurements.

24 Similarly to Lys236, Arg227 could harbour a role in membrane packing. In our experiments, R227S is one of  
25 the mutants that appeared to induce weaker adhesion than the wild-type protein. The mutation results in a  
26 loosened repeat structure without a major impact on protein folding, which could relate to the exposed  
27 negative charge of Asp224 causing repulsion towards an apposing bilayer. Arg227 might be involved in  
28 electrostatic anchoring of the protein to the lipid headgroups – the R227S mutation likely has low impact on  
29 ER stress and UPR, as mutated P0 correctly localizes to the plasma membrane [42].

### 30 **Concluding remarks**

31 To a large extent, the P0ct CMT variants studied here perform similarly to wt-P0ct in controlled simple  
32 environments. This might differ in vivo, where other components are present and P0 is present in its full-  
33 length form. Our characterization is focused on protein-lipid interactions and does not take into account  
34 possible protein-protein interactions with MBP, P2, or PMP22, which might be relevant for myelination and  
35 disease phenotypes. Nevertheless, we have uncovered critical amino acids in P0 that may contribute to the



1 formation of healthy myelin and be involved in disease mechanisms. These include Arg227, Lys236, and  
2 Asp224. Our results shed light on the molecular fundamentals of myelination in the PNS, but more  
3 comprehensive studies in biological model systems, as well as on molecular structure and dynamics of  
4 native-like myelin membranes, are needed for deciphering the mechanisms of the P0ct mutations causing  
5 human neuropathy.

## 1 **Experimental procedures**

### 2 **Bioinformatics, mutagenesis, protein expression & purification**

3 Secondary structure prediction for P0ct was performed using JPred [43]. Binding-induced folding was  
4 predicted with ANCHOR2/IUPred2 [44]. Mutations were generated in the P0ct pHMGWA expression vector  
5 [5,45] by PCR using Phusion High-Fidelity DNA polymerase (Thermo Fisher Scientific) with 5'-  
6 phosphorylated primers that introduced the desired point mutations. The samples were treated with DpnI  
7 (New England Biolabs) to digest template DNA and linear vectors circularized using T4 DNA ligase (New  
8 England Biolabs), followed by transformation and plasmid isolation. The presence of mutations and integrity  
9 of the constructs was verified using DNA sequencing.

10 Protein expression and purification were carried out in *E. coli* BL21(DE3) as described for wt-P0ct [5], with  
11 the exception of an added amylose-resin affinity step between Ni-NTA and size-exclusion chromatography.  
12 The step was introduced to remove any contaminating maltose-binding protein tags from the tobacco etch  
13 virus protease-digested recombinant proteins. Size exclusion chromatography was carried out using  
14 Superdex S75 16/60 HiLoad and Superdex 75 10/300GL columns (GE Healthcare) with 20 mM HEPES, 150  
15 mM NaCl, pH 7.5 (HBS) as mobile phase, with the exception of D224Y, where a 20 mM Tris-HCl, 300 mM  
16 NaCl, pH 8.5 (TBS) solution was used. The monodispersity and  $R_h$  of all proteins were checked from filtered  
17 1 mg/ml samples using a Malvern Zetasizer ZS DLS instrument. The D224Y mutant was then dialyzed into  
18 HBS. Additionally, all proteins were dialyzed into water prior to SRCD experiments.

19

### 20 **Mass spectrometry**

21 The molecular weight and identity of the purified proteins were verified by mass spectrometry. In short, the  
22 proteins were subjected to ultra-performance liquid chromatography (UPLC) coupled electrospray ionization  
23 (ESI) time-of-flight mass spectrometry in positive ion mode, using a Waters Acquity UPLC-coupled Synapt  
24 G2 mass analyzer with a Z-Spray ESI source. This allowed us to determine the undigested masses of each  
25 purified P0ct variant. Protein identity and the presence of the desired mutations were confirmed from  
26 peptides extracted after in-gel tryptic proteolysis, using a Bruker Ultra fleXtreme matrix-assisted laser  
27 desorption/ionization time-of-flight (MALDI-TOF) mass analyzer.

28

### 29 **Small-angle X-ray scattering**

30 SAXS data were collected from protein samples at 0.3 – 12.9 mg/ml in HBS and TBS on the EMBL P12  
31 beamline, PETRA III (Hamburg, Germany) [46]. Monomeric bovine serum albumin ( $M_r = 66.7$  kDa;  $I_0 =$   
32 499.0) was used as a molecular weight standard. Data were processed and analyzed using the ATSAS

1 package [47], and GNOM was used to calculate distance distribution functions [48]. See Supplementary  
2 Table S2 for further details.

3

#### 4 **Vesicle preparation**

5 DMPC, DMPG, and DOPC were purchased from Larodan Fine Chemicals AB (Malmö, Sweden). DOPS and  
6 the deuterated  $d_{54}$ -DMPC and  $d_{54}$ -DMPG were purchased from Avanti Polar Lipids (Alabaster, Alabama,  
7 USA).

8 Lipid stocks were prepared by dissolving dry lipids in chloroform or chloroform:methanol (9:1 v/v) at 10-30  
9 mM. Mixtures were prepared from stocks at the desired molar ratios, followed by solvent evaporation under  
10 a stream of nitrogen and lyophilizing overnight at -52 °C. The dried lipids were stored at -20 °C or used  
11 directly for liposome preparation.

12 Liposomes were prepared by mixing dried lipids with water or HBS at 10-15 mM, followed by inverting at  
13 ambient temperature for at least 3 h. Multilamellar vesicles (MLV) were prepared by freeze-thaw cycles in  
14 liquid  $N_2$  and a warm water bath and vortexing. The cycle was performed 7 times in total. Large unilamellar  
15 vesicles (LUV) were prepared by passing fresh MLVs through a 0.1- $\mu$ m membrane 11 times at 40 °C. SUVs  
16 were prepared by ultrasonication of fresh MLVs using a probe tip sonicator (Sonics & Materials Inc. Vibra-  
17 Cell VC-130) until clarified. All lipid preparations were immediately used in experiments.

18

#### 19 **Synchrotron radiation circular dichroism spectroscopy**

20 SRCD spectra were collected from 0.1 – 0.5 mg/ml protein samples in water on the AU-CD beamline at  
21 ASTRID2 synchrotron (ISA, Aarhus, Denmark). Samples containing lipids were prepared right before  
22 measurement by mixing proteins (P/L ratio 1:200) with SUVs. 100- $\mu$ m pathlength closed circular cells  
23 (Suprasil, Hellma Analytics) were used for the measurements. Spectra were recorded from 170 to 280 nm at  
24 30 °C. Baselines were subtracted and CD units converted to  $\Delta\epsilon$  ( $M^{-1} cm^{-1}$ ) in CDtoolX [49]. SDS and TFE  
25 were from Sigma-Aldrich and the detergents LDAO, OG, DM, and DPC from Affymetrix.

26 Rapid kinetic SRCD data were collected as described [21]. In short, an SX-20 stopped-flow instrument  
27 (Applied Photophysics) mounted on the AU-rSRCD branch line of the AU-AMO beamline at ASTRID2  
28 (ISA, Aarhus, Denmark) at was used for data collection at 10 °C. 1-to-1 mixing of a 0.1 mg/ml protein  
29 solution and a DMPC:DMPG (1:1) SUV solution (at P/L ratios 1:200) was achieved using a mixer (2 ms  
30 dead time) before injection into the measurement cell (160  $\mu$ l total volume, 2-mm pathlength) per shot. The  
31 CD signal (mdeg) was monitored at a fixed wavelength of 195 nm for 5 s with a total of 5 – 10 repeat shots  
32 per sample, which were averaged into a single curve. Each sample was prepared and measured in duplicate.

1 Water baselines were subtracted from sample data. The data were fitted to different exponential functions  
2 using GraphPad Prism 7.

3

#### 4 **Surface plasmon resonance**

5 SPR was performed on a Biacore T200 system (GE Healthcare). According to the manufacturer's  
6 instructions, 100-nm LUVs of 1 mM DMPC:DMPG (1:1) were immobilized on an L1 sensor chip (GE  
7 Healthcare) in HBS, followed by the injection of protein solutions. Chip regeneration was performed using a  
8 2:3 (v:v) mixture of 2-propanol and 50 mM NaOH. The protein concentration was 20 – 2000 nM in HBS,  
9 and a single concentration per lipid capture was studied; all samples were prepared and measured in  
10 duplicate. In each run, one sample was measured twice to rule out instrumental deviation. The binding  
11 response as a function of protein concentration was plotted and fitted to the 4-parameter model,

$$12 \quad R = R_{hi} - \frac{R_{hi} - R_{lo}}{1 + \left(\frac{[P]_{oct}}{A_1}\right)^{A_2}},$$

13 to gain information about association affinity.

14

#### 15 **Differential scanning calorimetry**

16 Proteins were mixed with MLVs in HBS at a protein-to-lipid ratio of 1:100 or 1:250, always containing 350  
17  $\mu$ M of DMPC:DMPG (1:1) in a final volume of 700  $\mu$ l. Lipid samples without proteins were prepared as  
18 controls. The samples were degassed for 10 min under vacuum with stirring at 10 °C before measurements.

19 DSC was performed using a MicroCal VP-DSC calorimeter with a cell volume of 527.4  $\mu$ l. The reference  
20 cell was filled with HBS. Each sample was scanned from 10 to 40 °C and back to 10 °C in 1 °C/min  
21 increments. Baselines were subtracted from sample curves and zeroed between 15 and 20 °C to enable  
22 straightforward comparison between samples. All samples were prepared and measured twice, with the  
23 observed trends being reproducible.

24

#### 25 **Vesicle turbidimetry and X-ray diffraction**

26 For turbidimetric measurements, SUVs of DMPC:DMPG (1:1) were mixed with 0.5 – 10  $\mu$ M protein in  
27 duplicate and mixed thoroughly. Turbidity was recorded at 450 nm at 30 °C using a Tecan Spark 20M plate  
28 reader. Turbidity of protein-free SUVs was subtracted from the protein samples, and statistical analysis was  
29 performed using GraphPad Prism 7.

30 SAXD experiments were performed to investigate repetitive structures in the turbid samples. 10 and 20  $\mu$ M  
31 proteins were mixed with SUVs of 1 – 3 mM DMPC:DMPG (1:1) in HBS at ambient temperature and

1 exposed at 25 °C on the EMBL P12 BioSAXS beamline, DESY (Hamburg, Germany). A HBS buffer  
2 reference was subtracted from the data. Lipid samples without added protein did not produce Bragg peaks.  
3 The peak positions of momentum transfer,  $s$ , in all measured samples were used to calculate mean repeat  
4 distances,  $d$ , in proteolipid structures, using the equation

$$5 \quad d = \frac{2\pi}{s}, \text{ where } s = \frac{4\pi\sin\theta}{\lambda}.$$

6

## 7 **Electron microscopy**

8 For negatively stained EM, 740  $\mu\text{M}$  DMPC:DMPG (1:1) SUVs were mixed with proteins using protein-to-  
9 lipid ratios of 1:58, 1:100, 1:200, and 1:500 and incubated at 22 °C for 1 h. EM grids were then prepared,  
10 stained and imaged as described before [5,20,50].

11

## 12 **Neutron reflectometry**

13 Supported lipid bilayers were prepared onto flat (5 Å RMS roughness tolerance) 80 mm  $\times$  50 mm  $\times$  15 mm  
14 Si-crystal blocks (Sil'tronix Silicon Technologies, Archamps, France). Samples were prepared from a  
15 chloroform-methanol stock of 1 mg/ml DMPC:DMPG (1:1). Using Langmuir-Blodgett and Langmuir-  
16 Schaefer techniques, the two membrane leaflets of the bilayers were deposited sequentially. The surface  
17 pressure was kept at a constant 30 mN m<sup>-1</sup> during the deposition, as described previously [20,51,52]. All  
18 sample blocks were assembled into low-volume measurement flow cells, which were used for in situ  
19 exchange of solvent and injection of protein samples between reflectometric data collections [53].

20 Neutron reflectometric measurements for wt-P0ct were performed as described [20]. In short, the D17  
21 neutron reflectometer at the Institut Laue-Langevin (Grenoble, France) was used for data collection at two  
22 incident angles (0.8° and 3.2°) [54]. All samples were kept at 30 °C with HBS buffer as the liquid phase,  
23 prepared at a final concentration of 95% (v/v) deuterium oxide (D<sub>2</sub>O, Sigma-Aldrich) and in H<sub>2</sub>O. The  
24 deposited bilayers were characterized, before and after the injection of P0ct, at three different solvent  
25 contrasts, varying the volume ratio of D<sub>2</sub>O and H<sub>2</sub>O in to the sample cell: (1) 95% D<sub>2</sub>O, (2) Si-matched water  
26 (SMW; 38% (v/v) D<sub>2</sub>O, 62% (v/v) H<sub>2</sub>O), and (3) 100% H<sub>2</sub>O. A 0.5  $\mu\text{M}$  P0ct solution was allowed to interact  
27 with the membrane for 3 h whilst monitoring reflectivity, until no further changes were observed. Any  
28 excess P0ct was washed out from the bulk solution by exchanging 20 cell volumes of solvent slowly through  
29 the sample cell. Fitting was performed using Motofit in Igor Pro 7 [55].

30 The scattering length densities of the phospholipids were calculated from volume fractions of the lipid  
31 components obtained from molecular dynamics simulations [56], and for the proteins, they were calculated  
32 from the sequences and amino acid volumes [57]. The P0ct scattering length density, assuming 90% labile

1 hydrogen exchange, was 3.227, 2.324, and  $1.722 \times 10^{-6} \text{ \AA}^{-2}$  in 95%, 38%, and 0% D<sub>2</sub>O, respectively. The  
2 errors in the structural parameters for each sublayer were derived from the maximum acceptable variation in  
3 the fitted thickness and lipid volume fraction that allowed a fit to be maintained, subject to a constant  
4 molecular area constraint required to maintain a planar bilayer geometry.

5 Details of the analysis of supported lipid membrane structure [58] and interaction with soluble proteins [59]  
6 using time-of-flight neutron reflection have been described previously. The fraction of P0 in the lipid  
7 bilayers was determined by a simultaneous fit to all contrasts, taking into account the change in protein  
8 scattering length density with solvent contrast due to H/D exchange of protons on polar residues with the  
9 solvent.

10 For mutant comparison to wt-P0ct, NR data for wt-P0ct and D224Y were collected on the INTER neutron  
11 reflectometer at ISIS Neutron and Muon Source (Didcot, United Kingdom) at two incident angles (0.7° and  
12 2.3°) [60] covering a total q-range from 0.01 to  $0.34 \text{ \AA}^{-1}$ , with a resolution of  $\Delta q/q=0.03$ . The samples were  
13 prepared and handled as above.

14

## 15 **Modelling**

16 A 3D model for the neuritogenic segment was made using PEP-FOLD [61]. The peptide was then subjected  
17 to MD simulations at +25 °C in water, using YASARA [62], essentially as described [63].

18

1 **Acknowledgements**

2 This work was financially supported by the Academy of Finland (Finland), the Jane and Aatos Erkkö  
3 Foundation (Finland), and the Norwegian Research Council (SYNKNØYT program). This work has been  
4 supported by iNEXT, grant number 653706, funded by the Horizon 2020 programme of the European  
5 Commission. The research leading to this result has been supported by the project CALIPSOplus under the  
6 Grant Agreement 730872 from the EU Framework Programme for Research and Innovation HORIZON  
7 2020. We gratefully acknowledge the synchrotron radiation facilities and the beamline support at ASTRID2  
8 and EMBL/DESY, as well as the ILL (Proposal No. 8-02-745) and STFC/ISIS (Proposal No. 1620422;  
9 doi:10.5286/ISIS.E.95673822). We express our gratitude towards the Biocenter Oulu Proteomics and Protein  
10 Analysis Core Facility for providing access to mass spectrometric instrumentation, as well as the Biophysics,  
11 Structural Biology, and Screening (BiSS) facilities at the University of Bergen. Finally, we thank Anushik  
12 Safaryan for practical help with liposome preparation.

13

## 1 **References**

- 2 1. Hartline DK (2008) What is myelin? *Neuron Glia Biol* 4: 153-163.
- 3 2. Stassart RM, Möbius W, Nave KA, Edgar JM (2018) The Axon-Myelin Unit in Development and  
4 Degenerative Disease. *Front Neurosci* 12: 467.
- 5 3. Shapiro L, Doyle JP, Hensley P, Colman DR, Hendrickson WA (1996) Crystal structure of the  
6 extracellular domain from P0, the major structural protein of peripheral nerve myelin. *Neuron* 17: 435-  
7 449.
- 8 4. Luo X, Sharma D, Inouye H, Lee D, Avila RL, Salmona M et al. (2007) Cytoplasmic domain of  
9 human myelin protein zero likely folded as beta-structure in compact myelin. *Biophys J* 92: 1585-  
10 1597.
- 11 5. Raasakka A, Ruskamo S, Kowal J, Han H, Baumann A, Myllykoski M et al. (2019) Molecular  
12 structure and function of myelin protein P0 in membrane stacking. *Sci Rep* 9: 642.
- 13 6. Wong MH, Filbin MT (1994) The cytoplasmic domain of the myelin P0 protein influences the  
14 adhesive interactions of its extracellular domain. *J Cell Biol* 126: 1089-1097.
- 15 7. de Sèze J, Kremer L, Alves do Rego C, Taleb O, Lam D, Beiano W et al. (2016) Chronic inflammatory  
16 demyelinating polyradiculoneuropathy: A new animal model for new therapeutic targets. *Rev Neurol*  
17 (Paris) 172: 767-769.
- 18 8. Mandich P, Fossa P, Capponi S, Geroldi A, Acquaviva M, Gulli R et al. (2009) Clinical features and  
19 molecular modelling of novel MPZ mutations in demyelinating and axonal neuropathies. *Eur J Hum*  
20 *Genet* 17: 1129-1134.
- 21 9. Shy ME, Jáni A, Krajewski K, Grandis M, Lewis RA, Li J et al. (2004) Phenotypic clustering in MPZ  
22 mutations. *Brain* 127: 371-384.
- 23 10. Su Y, Brooks DG, Li L, Lepercq J, Trofatter JA, Ravetch JV et al. (1993) Myelin protein zero gene  
24 mutated in Charcot-Marie-tooth type 1B patients. *Proc Natl Acad Sci U S A* 90: 10856-10860.
- 25 11. Fabrizi GM, Pellegrini M, Angiari C, Cavallaro T, Morini A, Taioli F et al. (2006) Gene dosage  
26 sensitivity of a novel mutation in the intracellular domain of P0 associated with Charcot-Marie-Tooth  
27 disease type 1B. *Neuromuscul Disord* 16: 183-187.
- 28 12. Miltenberger-Miltenyi G, Schwarzbraun T, Löscher WN, Wanschitz J, Windpassinger C, Duba HC et  
29 al. (2009) Identification and in silico analysis of 14 novel GJB1, MPZ and PMP22 gene mutations. *Eur*  
30 *J Hum Genet* 17: 1154-1159.
- 31 13. Schneider-Gold C, Kötting J, Epplen JT, Gold R, Gerding WM (2010) Unusual Charcot-Marie-Tooth  
32 phenotype due to a mutation within the intracellular domain of myelin protein zero. *Muscle Nerve* 41:  
33 550-554.
- 34 14. Street VA, Meekins G, Lipe HP, Seltzer WK, Carter GT, Kraft GH et al. (2002) Charcot-Marie-Tooth  
35 neuropathy: clinical phenotypes of four novel mutations in the MPZ and Cx 32 genes. *Neuromuscul*  
36 *Disord* 12: 643-650.
- 37 15. Choi BO, Lee MS, Shin SH, Hwang JH, Choi KG, Kim WK et al. (2004) Mutational analysis of  
38 PMP22, MPZ, GJB1, EGR2 and NEFL in Korean Charcot-Marie-Tooth neuropathy patients. *Hum*  
39 *Mutat* 24: 185-186.
- 40 16. Planté-Bordeneuve V, Parman Y, Guiochon-Mantel A, Alj Y, Deymeer F, Serdaroglu P et al. (2001)  
41 The range of chronic demyelinating neuropathy of infancy: a clinico-pathological and genetic study of  
42 15 unrelated cases. *J Neurol* 248: 795-803.
- 43 17. Bai Y, Patzko A, Shy ME (2013) Unfolded protein response, treatment and CMT1B. *Rare Dis* 1:  
44 e24049.
- 45 18. Bai Y, Wu X, Brennan KM, Wang DS, D'Antonio M, Moran J et al. (2018) Myelin protein zero  
46 mutations and the unfolded protein response in Charcot Marie Tooth disease type 1B. *Ann Clin Transl*  
47 *Neurol* 5: 445-455.
- 48 19. Wrabetz L, D'Antonio M, Pennuto M, Dati G, Tinelli E, Fratta P et al. (2006) Different intracellular  
49 pathomechanisms produce diverse Myelin Protein Zero neuropathies in transgenic mice. *J Neurosci*  
50 26: 2358-2368.
- 51 20. Raasakka A, Ruskamo S, Kowal J, Barker R, Baumann A, Martel A et al. (2017) Membrane  
52 Association Landscape of Myelin Basic Protein Portrays Formation of the Myelin Major Dense Line.  
53 *Sci Rep* 7: 4974.
- 54 21. Raasakka A, Jones NC, Hoffmann SV, Kursula P (2019) Ionic strength and calcium regulate



- 1 membrane interactions of myelin basic protein and the cytoplasmic domain of myelin protein zero.  
2 Biochem Biophys Res Commun 511: 7-12.
- 3 22. Ruskamo S, Yadav RP, Sharma S, Lehtimäki M, Laulumaa S, Aggarwal S et al. (2014) Atomic  
4 resolution view into the structure-function relationships of the human myelin peripheral membrane  
5 protein P2. Acta Crystallogr D Biol Crystallogr 70: 165-176.
- 6 23. Wang C, Neugebauer U, Bürck J, Myllykoski M, Baumgärtel P, Popp J et al. (2011) Charge isomers of  
7 myelin basic protein: structure and interactions with membranes, nucleotide analogues, and  
8 calmodulin. PLoS One 6: e19915.
- 9 24. Sedzik J, Blaurock AE, Hoechli M (1985) Reconstituted P2/myelin-lipid multilayers. J Neurochem 45:  
10 844-852.
- 11 25. Xu W, Shy M, Kamholz J, Elferink L, Xu G, Lilien J et al. (2001) Mutations in the cytoplasmic  
12 domain of P0 reveal a role for PKC-mediated phosphorylation in adhesion and myelination. J Cell Biol  
13 155: 439-446.
- 14 26. Vassall KA, Bamm VV, Harauz G (2015) MyelStones: the executive roles of myelin basic protein in  
15 myelin assembly and destabilization in multiple sclerosis. Biochem J 472: 17-32.
- 16 27. Lee M, Brennan A, Blanchard A, Zoidl G, Dong Z, Taberner A et al. (1997) P0 is constitutively  
17 expressed in the rat neural crest and embryonic nerves and is negatively and positively regulated by  
18 axons to generate non-myelin-forming and myelin-forming Schwann cells, respectively. Mol Cell  
19 Neurosci 8: 336-350.
- 20 28. Eichberg J (2002) Myelin P0: new knowledge and new roles. Neurochem Res 27: 1331-1340.
- 21 29. Lemke G, Axel R (1985) Isolation and sequence of a cDNA encoding the major structural protein of  
22 peripheral myelin. Cell 40: 501-508.
- 23 30. Suresh S, Wang C, Nanekar R, Kursula P, Edwardson JM (2010) Myelin basic protein and myelin  
24 protein 2 act synergistically to cause stacking of lipid bilayers. Biochemistry 49: 3456-3463.
- 25 31. Zenker J, Stettner M, Ruskamo S, Domènech-Estévez E, Baloui H, Médard JJ et al. (2014) A role of  
26 peripheral myelin protein 2 in lipid homeostasis of myelinating Schwann cells. Glia 62: 1502-1512.
- 27 32. Kidd GJ, Yadav VK, Huang P, Brand SL, Low SH, Weimbs T et al. (2006) A dual tyrosine-leucine  
28 motif mediates myelin protein P0 targeting in MDCK cells. Glia 54: 135-145.
- 29 33. Aggarwal S, Snaidero N, Pähler G, Frey S, Sánchez P, Zweckstetter M et al. (2013) Myelin membrane  
30 assembly is driven by a phase transition of myelin basic proteins into a cohesive protein meshwork.  
31 PLoS Biol 11: e1001577.
- 32 34. Greenfield S, Brostoff S, Eylar EH, Morell P (1973) Protein composition of myelin of the peripheral  
33 nervous system. J Neurochem 20: 1207-1216.
- 34 35. Patzig J, Jahn O, Tenzer S, Wichert SP, de Monasterio-Schrader P, Rosfa S et al. (2011) Quantitative  
35 and integrative proteome analysis of peripheral nerve myelin identifies novel myelin proteins and  
36 candidate neuropathy loci. J Neurosci 31: 16369-16386.
- 37 36. Filbin MT, Walsh FS, Trapp BD, Pizzey JA, Tennekoon GI (1990) Role of myelin P0 protein as a  
38 homophilic adhesion molecule. Nature 344: 871-872.
- 39 37. Maeda MH, Mitsui J, Soong BW, Takahashi Y, Ishiura H, Hayashi S et al. (2012) Increased gene  
40 dosage of myelin protein zero causes Charcot-Marie-Tooth disease. Ann Neurol 71: 84-92.
- 41 38. Martini R, Zielasek J, Toyka KV, Giese KP, Schachner M (1995) Protein zero (P0)-deficient mice  
42 show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies. Nat  
43 Genet 11: 281-286.
- 44 39. Quattrini A, Feltri ML, Previtali S, Fasolini M, Messing A, Wrabetz L (1999) Peripheral nerve  
45 dysmyelination due to P0 glycoprotein overexpression is dose-dependent. Ann N Y Acad Sci 883:  
46 294-301.
- 47 40. Speevak MD, Farrell SA (2013) Charcot-Marie-Tooth 1B caused by expansion of a familial myelin  
48 protein zero (MPZ) gene duplication. Eur J Med Genet 56: 566-569.
- 49 41. Wrabetz L, Feltri ML, Quattrini A, Imperiale D, Previtali S, D'Antonio M et al. (2000) P(0)  
50 glycoprotein overexpression causes congenital hypomyelination of peripheral nerves. J Cell Biol 148:  
51 1021-1034.
- 52 42. Lee YC, Lin KP, Chang MH, Liao YC, Tsai CP, Liao KK et al. (2010) Cellular characterization of  
53 MPZ mutations presenting with diverse clinical phenotypes. J Neurol 257: 1661-1668.
- 54 43. Drozdetskiy A, Cole C, Procter J, Barton GJ (2015) JPred4: a protein secondary structure prediction  
55 server. Nucleic Acids Res 43: W389-94.

- 1 44. Mészáros B, Erdos G, Dosztányi Z (2018) IUPred2A: context-dependent prediction of protein disorder  
2 as a function of redox state and protein binding. *Nucleic Acids Res* 46: W329-W337.
- 3 45. Busso D, Delagoutte-Busso B, Moras D (2005) Construction of a set Gateway-based destination  
4 vectors for high-throughput cloning and expression screening in *Escherichia coli*. *Anal Biochem* 343:  
5 313-321.
- 6 46. Blanchet CE, Spilotros A, Schwemmer F, Graewert MA, Kikhney A, Jeffries CM et al. (2015)  
7 Versatile sample environments and automation for biological solution X-ray scattering experiments at  
8 the P12 beamline (PETRA III, DESY). *J Appl Crystallogr* 48: 431-443.
- 9 47. Franke D, Petoukhov MV, Konarev PV, Panjkovich A, Tuukkanen A, Mertens HDT et al. (2017)  
10 ATSAS 2.8: a comprehensive data analysis suite for small-angle scattering from macromolecular  
11 solutions. *J Appl Crystallogr* 50: 1212-1225.
- 12 48. Svergun DI (1992) Determination of the regularization parameter in indirect-transform methods using  
13 perceptual criteria. *J Appl Cryst* 25: 495-503.
- 14 49. Miles AJ, Wallace BA (2018) CDtoolX, a downloadable software package for processing and analyses  
15 of circular dichroism spectroscopic data. *Protein Sci* 27: 1717-1722.
- 16 50. Ruskamo S, Nieminen T, Kristiansen CK, Vatne GH, Baumann A, Hallin EI et al. (2017) Molecular  
17 mechanisms of Charcot-Marie-Tooth neuropathy linked to mutations in human myelin protein P2. *Sci*  
18 *Rep* 7: 6510.
- 19 51. Barker RD, McKinley LE, Titmuss S (2016) Neutron Reflectivity as a Tool for Physics-Based Studies  
20 of Model Bacterial Membranes. *Adv Exp Med Biol* 915: 261-282.
- 21 52. Hubbard AT, Barker R, Rehal R, Vandera KA, Harvey RD, Coates AR (2017) Mechanism of Action  
22 of a Membrane-Active Quinoline-Based Antimicrobial on Natural and Model Bacterial Membranes.  
23 *Biochemistry* 56: 1163-1174.
- 24 53. Junghans A, Watkins EB, Barker RD, Singh S, Waltman MJ, Smith HL et al. (2015) Analysis of  
25 biosurfaces by neutron reflectometry: from simple to complex interfaces. *Biointerphases* 10: 019014.
- 26 54. Cubitt R, Fragneto G (2002) D17: the new reflectometer at the ILL. *Applied Physics A* 74: s329-s331.
- 27 55. Nelson A (2006) Co-refinement of multiple-contrast neutron/X-ray reflectivity data using MOTOFIT.  
28 *J Appl Crystallogr* 39: 273-276.
- 29 56. Armen RS, Uitto OD, Feller SE (1998) Phospholipid component volumes: determination and  
30 application to bilayer structure calculations. *Biophys J* 75: 734-744.
- 31 57. Zamyatnin AA (1972) Protein volume in solution. *Prog Biophys Mol Biol* 24: 107-123.
- 32 58. Vacklin HP, Tiberg F, Fragneto G, Thomas RK (2005) Composition of supported model membranes  
33 determined by neutron reflection. *Langmuir* 21: 2827-2837.
- 34 59. Wacklin HP, Bremec BB, Moulin M, Rojko N, Haertlein M, Forsyth T et al. (2016) Neutron reflection  
35 study of the interaction of the eukaryotic pore-forming actinoporin equinatoxin II with lipid  
36 membranes reveals intermediate states in pore formation. *Biochim Biophys Acta* 1858: 640-652.
- 37 60. Webster J, Holt S, Dalglish R (2006) INTER the chemical interfaces reflectometer on target station 2  
38 at ISIS. *Physica B: Condensed Matter* 385: 1164-1166.
- 39 61. Maupetit J, Derreumaux P, Tufféry P (2010) A fast method for large-scale de novo peptide and  
40 miniprotein structure prediction. *J Comput Chem* 31: 726-738.
- 41 62. Krieger E, Vriend G (2015) New ways to boost molecular dynamics simulations. *J Comput Chem* 36:  
42 996-1007.
- 43 63. Ponna SK, Myllykoski M, Boeckers TM, Kursula P (2017) Structure of an unconventional SH3  
44 domain from the postsynaptic density protein Shank3 at ultrahigh resolution. *Biochem Biophys Res*  
45 *Commun* 490: 806-812.
- 46

47

## 1 **Supplementary information**

2

3 **Supplementary Fig. S1. Protein yield.** The purified protein amount from *E. coli* expression, shown as mg  
4 of protein obtained per 1 l of culture.

5 **Supplementary Fig. S2. The folding of P0ct variants in TFE, detergents, and poorly binding**  
6 **membrane compositions.** The folding of wt-P0ct and mutants was studied using SRCD spectropolarimetry  
7 in (a) 10% TFE, (b) 50% TFE, (c) 70% TFE, (d) 0.1% DPC, (e) 1% LDAO, (f) 1% OG, (g) DMPC, and (h)  
8 9:1 DMPC:DMPG. The colour coding legend in panel (a) for each mutant trace also corresponds to all other  
9 traces in subsequent panels.

10 **Supplementary Fig. S3. P0ct variant-induced turbidimetry and diffraction.** (a) Turbidimetric analysis of  
11 0.5 mM DMPC:DMPG (1:1) vesicles in the presence of 0 – 10  $\mu$ M wt-P0ct and mutants. BSA was included  
12 as negative control. Error bars represent standard deviation. (b) Examples of Bragg peaks from the P0ct  
13 samples mixed with DMPC:DMPG (1:1) vesicles.

14 **Supplementary Fig. S4. EM analysis of P0ct D224Y.** Negatively stained samples of DMPC:DMPG (1:1)  
15 vesicles mixed with P0ct D224Y at (a) 1:100, (b) 1:200, and (c) 1:500 P/L ratios all display multilayered  
16 lipid structures.

17 **Supplementary Fig. S5. NR data of wt-P0ct and D224Y.** NR data for DMPC:DMPG (1:1)-bound wt-P0ct  
18 and D224Y. The data have been offset for clarity. Solvent contrasts are indicated for each trace on their right  
19 hand side. The D224Y H<sub>2</sub>O data is incomplete as reflectivity was collected at only one measurement angle  
20 (0.7°). The error bars denote standard deviation.

21 **Supplementary Table S1.** DLS parameters.

22 **Supplementary Table S2.** SAXS parameters.

23 **Supplementary Table S3.** DSC fitting results.

24

25